Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2018 · 10-Q
Revenue$90.43M$90.43M+57.1% vs Q1 2017 Net Income$26.35M$26.35M+155.9% vs Q1 2017 EPS Diluted$0.49$0.49+157.9% vs Q1 2017 Operating Income$31,394,000+87.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$26,880,000+105.9% Margins · derivedOperating margin34.7%+5.6 pt vs Q1 2017
Net margin29.1%+11.3 pt vs Q1 2017
ended Mar 31, 2018 · filed May 10, 2018 · 40 d after period end